The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation

Zeng, Jie; Shu, Qinglan; Lu, Cong; Wang, Yi

doi:10.1002/ehf2.14291

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonsurgical, transcatheter mitral interventions have been proposed for both obstructive [52] and nonobstructive [53] phenotypes with significant mitral regurgitation. In patients with LVOTO who are not candidates for SRT via myectomy or ASA, transcatheter mitral interventions have been performed with success in small numbers [54].…”

Section: Future Directionsmentioning

confidence: 99%

The mitral valve in hypertrophic cardiomyopathy

Malcolmson

Shipolini

Mohiddin

et al. 2023

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of review Whilst abnormally increased left ventricular wall thickness is the hallmark feature of hypertrophic cardiomyopathy (HCM), anomalies of the mitral valve and supporting apparatus are well documented. This review addresses the clinical importance of mitral valve abnormalities in HCM, their mechanistic associations with symptoms, and therapeutic strategies targeting mitral valve and apparatus abnormalities. Recent findings The normal mitral valve possesses anatomical features facilitating unrestricted blood flow during LV filling, preventing regurgitation during LV systole, and avoiding obstruction of LV ejection. In HCM, a variety of structural and functional abnormalities can conspire to cause deranged mitral valve function, with implications for management strategy. Identification and characterization of these abnormalities is facilitated by multimodality imaging. Alcohol septal ablation (ASA) cannot address primary mitral valve abnormalities, and so is not preferred to surgical intervention if mitral valve abnormalities are present and are judged to make dominant contributions to LV outflow tract obstruction (LVOTO). Two broadly opposing surgical intervention strategies exist, one advocating isolated septal myectomy and the other including adjuvant mitral apparatus modification. Newer, less invasive surgical and transcatheter techniques will expand interventional options. Summary Mitral valve abnormalities are a central pathological feature of HCM. Multimodality imaging is crucial for their identification and characterization prior to therapeutic intervention.

show abstract

Section: Future Directionsmentioning

confidence: 99%

The mitral valve in hypertrophic cardiomyopathy

Malcolmson

Shipolini

Mohiddin

et al. 2023

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation

Zeng

Shu

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

Reports on the treatment of nonobstructive hypertrophic cardiomyopathy (HCM) and severe mitral valve regurgitation (MR) with transcatheter edge‐to‐edge repair (TEER) are rare. Herein, we present the case of a 68‐year‐old Chinese man with nonobstructive HCM admitted to our hospital with dyspnoea [New York Heart Association (NYHA) functional Class IV]. Transthoracic echocardiography indicated severe MR in addition to asymmetric hypertrophy of the left ventricle. Despite administering maximal medical therapy for heart failure, the symptoms were not alleviated; because of the high risk of open surgery, TEER was performed for MR. After 4 months of follow‐up, the patient showed a significant improvement in symptoms. Herein, we also discuss and review the pathophysiology and treatment strategies for HCM patients with heart failure.

show abstract

The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation

Cited by 2 publications

References 18 publications

The mitral valve in hypertrophic cardiomyopathy

The mitral valve in hypertrophic cardiomyopathy

The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation

Contact Info

Product

Resources

About